NCT04623099View on ClinicalTrials.gov

Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)

PHASE4RecruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

March 8, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

December 1, 2026

Conditions
Anxiety
Interventions
DRUG

Escitalopram

Escitalopram is FDA-approved for the treatment of major depressive disorder (MDD) in adolescents (12-17 years of age) and is commonly prescribed for adolescents with anxiety disorders.

Trial Locations (1)

45219

RECRUITING

University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, Cincinnati

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of Cincinnati

OTHER